rapid cloning high-affinity human monoclonal antibodies influenza virus 
pre existing neutralizing antibody provides first line defence pathogens general influenza virus annual vaccinations given maintain protective levels antibody currently circulating strains report booster vaccination rapid robust influenza-specific igg+ antibody secreting plasma cell asc response peaked approximately day accounted % peripheral blood b cells ascs distinguished influenza specific igg+ memory b cells peaked days vaccination averaged % b cells importantly much % ascs purified peak response influenza specific asc response characterized highly restricted b cell receptor bcr repertoire donors dominated b cell clones pauciclonal response however showed extensive intraclonal diversification accumulated somatic mutations used immunoglobulin variable regions isolated sorted single ascs produce human monoclonal antibodies mabs bound three influenza vaccine strains high affinity strategy demonstrates can generate multiple high-affinity mabs humans within month vaccination panel influenza virus specific human mabs allowed us address issue original antigenic sin oas: phenomenon induced antibody shows higher affinity previously encountered influenza virus strain compared virus strain present vaccine however found influenza virus specific mabs showed highest affinity current vaccine strain thus oas seem common occurrence normal healthy adults receiving influenza vaccination 
